Matthews, Jessie;
Dobra, Rebecca;
Wilson, Gemma;
Allen, Lucy;
Bossley, Cara;
Brendell, Rebecca;
Brugha, Rossa;
... Davies, Jane C; + view all
(2024)
Levelling the playing field through the London Network of the UK clinical trials accelerator platform.
Contemporary Clinical Trials Communications
, 39
, Article 101301. 10.1016/j.conctc.2024.101301.
Preview |
Text
1-s2.0-S2451865424000486-main.pdf - Published Version Download (1MB) | Preview |
Abstract
Cystic fibrosis (CF) is a multisystem, genetic disease with a significantly reduced life expectancy. Despite substantial progress in therapies in the last 10-15 years, there is still no cure. There are dozens of drugs in the development pipeline and multiple clinical trials are being conducted across the globe. The UK Cystic Fibrosis Trust's (CFT) Clinical Trials Accelerator Platform (CTAP) is a national initiative bringing together 25 UK based CF centres to support the CF community in accessing and participating in CF clinical trials. CTAP enables more CF centres to run a broader portfolio of trials and increases the range of CF studies available for UK patients. There are four large specialist CF centres based in London, all within a small geographical region as well as two smaller centres which deliver CF care. At the launch of CTAP, these centres formed a sub-network in a consortium-style collaboration. The purpose of the network was to ensure equity of access to trials for patients across the UK's capital, and to share experience and knowledge. Four years into the programme we have reviewed our practices through working group meetings and an online survey. We sought to identify strengths and areas for improvement. We share our findings here, as we believe they are relevant to others delivering research in regions outside of London and in other chronic diseases.
Archive Staff Only
 |
View Item |
